Performance of VTGN VistaGen Therapeutics | 7.6% in 12m
Compare VTGN with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare VistaGen Therapeutics with its related Sector/Index XBI
Performance Duell VTGN vs XBI
| TimeFrame | VTGN | XBI |
|---|---|---|
| 1 Day | -2.42% | -1.52% |
| 1 Week | -1.99% | 1.45% |
| 1 Month | -6.72% | 10.08% |
| 3 Months | -11.2% | -1.30% |
| 6 Months | 26.9% | 24.09% |
| 12 Months | 7.64% | 6.83% |
| YTD | -13.8% | 1.05% |
| Rel. Perf. 1m | -1.27 | |
| Rel. Perf. 3m | -1.44 | |
| Rel. Perf. 6m | 0.94 | |
| Rel. Perf. 12m | -0.14 |
Is VistaGen Therapeutics a good stock to buy?
Probably not. Based on ValueRay Analyses, VistaGen Therapeutics (NASDAQ:VTGN) is currently (May 2024)
not a good stock to buy. It has a ValueRay Growth Rating of -3.47 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of VTGN as of May 2024 is 4.48. This means that VTGN is currently overvalued and has a potential downside of 0.9% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of VTGN as of May 2024 is 4.48. This means that VTGN is currently overvalued and has a potential downside of 0.9% (Sold with Premium).
Is VTGN a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
Values above 0%: VTGN is performing better - Values below 0%: VTGN is underperforming
Compare VTGN with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -3.63% | -13.65% | 9.47% | -20.67% |
| US NASDAQ 100 | QQQ | -3.95% | -15.67% | 10.80% | -27.51% |
| US Dow Jones Industrial 30 | DIA | -3.38% | -12.18% | 12.08% | -14.27% |
| German DAX 40 | DBXD | -1.75% | -11.87% | 9.70% | -6.74% |
| UK FTSE 100 | ISFU | -3.53% | -16.27% | 10.62% | -7.01% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -3.14% | -11.45% | 24.74% | 14.92% |
| Hongkong Hang Seng | HSI | -4.14% | -29.58% | 23.17% | 13.05% |
| Japan Nikkei 225 | EXX7 | -3.05% | -7.60% | 15.08% | -3.09% |
| India NIFTY 50 | INDA | -4.41% | -9.92% | 9.28% | -22.18% |
| Brasil Bovespa | EWZ | -1.90% | -10.01% | 30.62% | -5.07% |
VTGN VistaGen Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -3.18% | -10.67% | 9.68% | -28.14% |
| Consumer Discretionary | XLY | -2.46% | -11.99% | 20.07% | -11.19% |
| Consumer Staples | XLP | -3.04% | -11.78% | 12.54% | 1.61% |
| Energy | XLE | -3.46% | -6.71% | 12.90% | -15.72% |
| Financial | XLF | -3.98% | -11.95% | 4.93% | -25.02% |
| Health Care | XLV | -3.98% | -12.02% | 12.55% | -5.61% |
| Industrial | XLI | -2.13% | -10.75% | 7.53% | -20.07% |
| Materials | XLB | -2.39% | -10.31% | 11.04% | -11.96% |
| Real Estate | XLRE | -4.23% | -14.75% | 18.06% | -3.22% |
| Technology | XLK | -4.56% | -16.74% | 12.20% | -27.96% |
| Utilities | XLU | -3.49% | -17.28% | 8.30% | -5.55% |
| Aerospace & Defense | XAR | -3.06% | -15.08% | 12.61% | -16.79% |
| Biotech | XBI | -3.44% | -16.80% | 2.77% | 0.81% |
| Homebuilder | XHB | -2.57% | -13.72% | -3.40% | -43.21% |
| Retail | XRT | -1.51% | -13.41% | 6.76% | -21.86% |
Does VistaGen Therapeutics outperform its market, is VTGN a Sector Leader?
Yes, over the last 12 months VistaGen Therapeutics (VTGN) made 7.64%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months VTGN made -11.20%, while XBI made -1.30%.
Yes, over the last 12 months VistaGen Therapeutics (VTGN) made 7.64%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months VTGN made -11.20%, while XBI made -1.30%.
| Period | VTGN | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -6.72% | 10.08% | 6.93% |
| 3 Months | -11.20% | -1.30% | 6.91% |
| 12 Months | 7.64% | 6.83% | 28.31% |